RNAscope® in situ hybridization to detect prostate cancer-related markers

RNAscope<sup>®</sup> 2.5 LS Red - Prostate Cancer - PPIB

in situ hybridization of PPIB in prostate cancer tissue with RNAscope® 2.5 LS Reagent Kit - RED

RNA expression of PCGEM1 gene in human prostate cancer tissue using RNAscope<sup>®</sup> 2.5 HD Assay Brown RNA in situ hybridization (ISH)

RNA expression of PCGEM1 gene in human prostate cancer tissue using RNAscope® 2.5 HD Assay Brown

RNA expression of SCHLAP1 gene in human prostate cancer tissue using RNAscope<sup>®</sup> 2.5 HD Assay Brown RNA in situ hybridization (ISH)

RNA expression of SCHLAP1 gene in human prostate cancer tissue using RNAscope® 2.5 HD Assay Brown

Expression of prostate cancer biomarker PCA3 RNA (brown dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope<sup>®</sup> 2.0 HD Reagent Kit-BROWN

Expression of PCA3 RNA (brown dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope® 2.0 HD Reagent Kit-BROWN

Expression of prostate cancer biomarker TP63 RNA (red dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope<sup>®</sup> 2.0 HD Reagent Kit-RED

Expression of TP63 RNA (red dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope® 2.0 HD Reagent Kit-RED

Expression of prostate cancer biomarker TP63 RNA (red dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope<sup>®</sup> 2.0 HD Reagent Kit-RED

Expression of TP63 RNA (red dots) in human prostate cancer tissue, RNA in situ hybridization (ISH) using RNAscope® 2.0 HD Reagent Kit-RED

RNAscope® in situ hybridization (ISH) offers a reliable and robust method for the detection and validation of prostate cancer (PCa)-related biomarkers within the tissue environment. 

How RNAscope® ISH has been applied to examine PCa-related markers:

  • Reactivation of WNT by SOX9 drives PCa:
    SOX9 has been implicated in PCa but the SOX9-dependent genes and pathways involved are not well known. Ma et al. used SOX9 ChIP-Seq and transcriptome profiling to identify the spectrum of SOX9-related genes and pathways in PCa. A microarray gene set enrichment was performed on the prostate cancer cell line VCaP after knockdown of SOX9 and showed that SOX9 positively regulated WNT pathway genes such as AXIN2, FZD5, and FZD7. RNAscope® ISH validated the microarray results in human PCa samples and showed that SOX9 levels correlated with WNT pathway components.

    SOX9 drives WNT pathway activation in prostate cancer

  • Correlation of the lncRNA SChLAP1 with PCa disease progression:
    Mehra et al. used RNAscope® ISH to demonstrate that PCa patients with high expression of the lncRNA SChLAP1 had a significantly higher chance of developing lethal disease, suggesting SChLAP1 could be a tissue-based prostate cancer biomarker for identifying PCa patients at higher risk of lethal progression. The RNAscope® assay is a unique method in patient-derived FFPE samples to study the expression of lncRNAs, for which antibody detection is just not possible.

    Overexpression of the long non-coding RNA SChLAP1 independently predicts lethal prostate cancer.

  • Identification of the cellular localization of the secreted factor IL6 in PCa:
    IL6 is known to contribute to the development and/or progression of PCa, however the source of IL6 production has not been determined. Yu et al. used RNAscope® ISH to reveal that IL6 expression was nearly exclusively restricted to the prostate stromal compartment and no IL6 was detected in primary and metastatic prostate adenocarcinoma cells. These findings suggest that paracrine IL6 and not autocrine IL6 is associated with PCa disease progression.

    A paracrine role for IL6 in prostate cancer: Lack of production by primary or metastatic tumor cell

Recorded Webinar

Watch the recorded webinar "Elucidating tumor heterogeneity in prostate cancer by combined IHC & novel RNA ISH"  presented by Nallasivam Palanisamy, PhD, Associate Scientist Department of Urology Henry Ford Health System, Detroit, MI.

Watch Webinar

Researchers in the Spotlight

In our Researcher in the Spotlight Section you can learn how other researchers use RNAscope® technology to help them advance their research in unique ways by adding morphological context to RNA expression analysis, and more.

Interview with Dr Rohit Mehra:
"Realising the potential of Iong noncoding RNA as a cancer biomarker - From NGS discovery to validation with RNA in situ Hybridization"

Interview with Dr Nallasivam Palanisamy:
"Development of Prostate Cancer Personalized Medicine - Advancing analysis of prostate tumor molecular heterogeneity by combined immunohistochemistry and novel RNA in situ hybridization"

Related Publications

RNAscope® ISH has been applied and published in many prostate cancer articles. 

X
Contact Us

Complete one of the two forms below and we will get back to you.

Advanced Cell Diagnostics

Our new headquarters office starting May 2016:

7707 Gateway Blvd.  
Newark, CA 94560
Toll Free: 1 (877) 576-3636
Phone: (510) 576-8800
Fax: (510) 576-8798

 

Advanced Cell Diagnostics , S.r.l.

Via Calabria15
20090 Segrate (Milano) - Italy

Phone: +39.02.95360323
Fax: +39.02.95360992
For European orders: order_europe@acdbio.com

Advanced Cell Diagnostics China

Building 15, No. 26 Xihuan South Road
Beijing Economic-Technological Development Area
Beijing, China, Zip code: 100176

400-966-1796
info_china@acdbio.com
For general information: Leon Li lli@acdbio.com
Web: www.acdbio.com.cn

For general information: info@acdbio.com
For place an order: order@acdbio.com
For product support: support@acdbio.com
For career opportunities: hr@acdbio.com